Skip to main content

Table 1 A summary of the 14 including RCT studies with medication interventions assessing the restricted/repetitive behavior in autism spectrum disorders patients

From: Pharmacotherapy of restricted/repetitive behavior in autism spectrum disorder:a systematic review and meta-analysis

StudyParticipants (Age range)Participants sex distributionParticipants RaceSample sizeDiagnostic criteriaInterventionComparisonIntervention vs placeboAssessment scalesResultIncluded in metaanalysis
McDougle et. al., 1996 [30]18- 5327 male /3 femaleNot reported30ICD10fluvoxamine 15 (50 - 300mg/day)Placebo15vs15Y-BOCSpositiveIncluded
McDougle et.al.,1998 [31]18-4322 male/9 female6 African Americans, 24 whites, and 1 Hispanic31DSM-IV-TRrisperidone,15 (1-10 mg/day)Placebo15vs16Y-BOCSpositiveIncluded
Hollander et. al., 2005 [32]5–1630 male -9 female57% of the subjects were Caucasian, 23% Black, 15% Hispanic and 5% Asian39DSM-IV-TRFluoxetine,20 (0.8 mg/kg/day)Placebo20vs19Y-BOCSnegativeIncluded
Hollander et.al., 2006 [33]5-17 (one is 40)Not reportedEight of the subjects were Caucasian, two were African American, two were Asian and one was Hispanic13DSM-IV-TRDivalproex sodium,9 (125 mg/d)Placebo9vs4CY-BOCSpositive 
Wasserman et.al., 2006 [34]5–1717 male /3 female50% Caucasian, 35% African American, 5% Asian, and 10% Hispanic.20DSM-IV-TRlevetiracetam, 10 (125 - 250mg/day)Placebo10vs10CY-BOCSnegative 
Hollander et. al., 2006 [35]14-69 male /2 female7 Caucasian, 1 Hispanic, 1 Asian, and 2 African American11DSM-IV-TROlanzapine,6 (2.5-20 mg/day)Placebo6vs5CY-BOCSnegative 
King et. al., 2009 [36]17-5128 male/21 femaleWhite 108 Black 17 Asian 14 Other 11149DSM-IV-TRCitalopram,73 2.5-20mg/d.)Placebo73vs76CY-BOCSnegativeIncluded
Anagnostou. et. al., 2012 [37]mean(33.2 ±13.3)16 male /3 femaleCaucasian 14 Black 1 Hispanic 1 Asian 1 other 119DSM-IV-TROxytocin,10 (4 8IU/d)Placebo10vs9Y-BOCS&RBS-RRBS-R low prder 0.045Included
Hardan et. al., 2012 [38]3.2–10.72 male /31 femalenot clear33DSM-IV-TRNAcetylcysteine, 15 (900-2700 mg/day)Placebo15vs18Y-BOCS&RBS-RRBS-R stereotypies 0.014Included
Hollander et al., 2012 [39]18-6026 male /11 female57% of the subjects were Caucasian, 23% Black, 15% Hispanic and 5% Asian37DSM-IV-TRfluoxetine, 22 (10-80mg/day)Placebo22vs15CY-BOCSpositiveIncluded
Kent et. al.,2012 [40]5 -1712 male /84 femaleWhite 67 Black 19 Asian 7 Other 396DSM-IV-TRRisperidone (0.125 mg/day [20 to\45 kg], 0.175 mg/day [[45 kg]), 20 Risperidone (high dose1.25 mg/day [20 to \45 kg], 1.75 mg/day [[45 kg])),31Placebo20vs31vs35ABC&CYBOCSpositive 
Diane C. Chugani et al. 2016 [41]2 -<6137 male/29 femaleAmerican Indian or Alaskan 1 Asian 2 black 51 hawaiian white 97 other 12166DSM-IV-TRBuspirone (2.5 mg/Ml, low dose),54 Buspirone (5 mg/Ml, high dose),55Placebo54vs55vs57Y-BOCS&RBSpositiveIncluded
Dean et al., 2017 [42]3-979 male/19 femaleAustralia and Anglo-Saxon102DSM-IV-TRN-acetyl cysteine,51 (500 - 2000mg/day)Placebo51vs51RBS-RnegativeIncluded
Parker et. al., 2017 [43]6–1227 male /5 femaleCaucasian Asian32DSM-IV-TRoxytocin, 14 (18-24IU/d)Placebo14vs18RBS-RnegativeIncluded
  1. ASD autism spectrum disorder, DSM-IV-TR Diagnostic and Statistical Manual IV text revision, ICD-10 International Classification of Disease, Tenth Revision, RBS-R Repetitive Behavior Scale - Revised, Y-BOCS Yale–Brown Obsessive–Compulsive Scale, CY-BOCS Children Yale–Brown Obsessive–Compulsive Scale